Orthonotes
Orthonotes
by the.bonestories
v4.1 Fusion X
v4.1 Fusion X
Arthroplasty 288 views 977 words 5 min read

Heterotopic Ossification after Hip Arthroplasty

Key Takeaway
HO = abnormal bone formation in periarticular soft tissues after surgery or trauma. Incidence after THA: 20–50%; clinically significant in 5–10%. Risk factors: male sex, hypertrophic OA, ankylosing spondylitis, previous HO. Classification: Brooker I–IV (X-ray based). Prophylaxis: NSAIDs, radiotherapy; treatment = excision if severe functional limitation.
Published Feb 28, 2026 Updated Oct 02, 2026 By The Bone Stories ✓ Admin
Overview & Pathophysiology

Heterotopic ossification (HO) — the formation of mature lamellar bone in soft tissues where bone does not normally exist — is a recognised complication of total hip arthroplasty (THA), occurring in varying degrees in approximately 10–50% of patients after THA on routine radiographic screening, though clinically significant HO (causing pain and restricted motion) affects only approximately 5–15%. HO forms in the periarticular musculature and fascial planes around the hip, most commonly in the anterior and lateral soft tissues. Severe HO can cause significant restriction of hip motion — particularly flexion and abduction — and may require surgical excision in refractory cases.

  • Pathophysiology: HO is driven by osteogenic precursor cells (mesenchymal stem cells) in the periarticular soft tissues that are triggered to undergo ectopic ossification by the local surgical trauma and inflammatory milieu; bone morphogenetic proteins (BMPs — particularly BMP-2 and BMP-7) released from disrupted bone and soft tissue during surgery act as potent osteoinductive signals; the surgical approach, degree of soft tissue trauma, and bleeding into the wound all influence the osteogenic stimulus; the resulting bone forms as mature lamellar bone (not woven bone or calcification) — hence the term `ossification` rather than `calcification`; it takes approximately 12–18 months to fully mature (confirmed by falling uptake on radionuclide bone scan)
  • Risk factors: prior HO (the strongest predictor — approximately 90% recurrence risk without prophylaxis after excision); hypertrophic osteoarthritis as the indication for THA (prominent osteophytes indicate a hyperactive osteogenic response); ankylosing spondylitis (HO is particularly severe and aggressive in AS); prior hip or pelvic surgery or radiotherapy; male sex; diffuse idiopathic skeletal hyperostosis (DISH); Paget`s disease of bone; neuromuscular disease (spinal cord injury, traumatic brain injury — the highest risk population for HO outside arthroplasty)
Classification — Brooker Classification
Brooker Class Radiographic Appearance Clinical Significance
Class I Islands of bone in soft tissues around the hip — not bridging Usually asymptomatic; no functional limitation
Class II Bone spurs from the pelvis or femur; gap between opposing bone surfaces >1 cm Mild; usually asymptomatic or minor stiffness
Class III Bone spurs from pelvis AND femur; gap <1 cm Moderate; clinically significant restriction of motion — restricted flexion and abduction; pain
Class IV Apparent bony ankylosis of the hip Severe; near-complete loss of hip motion; the patient may have a painless fused hip (functionally usable for walking) or a painful ankylosed hip; surgical excision may be required
Prophylaxis
  • NSAIDs — indomethacin: the most widely used pharmacological prophylaxis; indomethacin 25 mg three times daily for 6 weeks post-operatively; inhibits prostaglandin synthesis via COX inhibition — prostaglandins are key mediators of osteoblast differentiation and the osteogenic response to surgical trauma; evidence shows approximately 50–75% reduction in clinically significant HO with indomethacin prophylaxis; concerns — GI side effects (dyspepsia, ulceration); renal impairment; possible impairment of fracture healing and bone ingrowth of cementless implants (NSAIDs inhibit bone healing — theoretical concern in the context of cementless THA; this is debated and most evidence suggests that 6 weeks of NSAIDs does not impair cementless fixation in standard cases); alternative NSAIDs (celecoxib, diclofenac) are also used
  • Radiotherapy: single-fraction external beam radiotherapy (7 Gy) administered within 72 hours of surgery (pre- or post-operatively) is an effective alternative to NSAIDs; particularly used in high-risk patients (prior HO, AS, DISH, hypertrophic OA, prior RT, patients who cannot take NSAIDs); radiotherapy inhibits osteogenic precursor cells in the periarticular tissues; the dose of 7 Gy is subthreshold for wound healing complications but sufficient to ablate local osteogenic progenitors; theoretical cancer risk (very low with single 7 Gy fraction); must be given within 72 hours (osteogenic cascade begins rapidly after surgical trauma); prophylactic RT and NSAIDs are broadly equivalent in efficacy for standard-risk patients; RT is preferred for high-risk patients
  • Both prophylaxis options can be combined in the highest-risk patients (e.g., prior severe HO requiring excision with recurrence risk ~90%)
Surgical Excision
  • Timing of excision: HO must be fully mature before surgical excision; immature HO has a high recurrence rate after excision; maturity is confirmed by: (1) radiographic appearance — mature lamellar bone with cortical margins on plain X-ray (as opposed to fluffy `cloud-like` immature calcification); (2) radionuclide bone scan — falling or normalised uptake indicates maturation (typically 12–18 months post-surgery); (3) biochemical markers — normalised alkaline phosphatase (elevated during active HO formation); excision before maturation (typically before 12–18 months) leads to recurrence in ~80% of cases
  • Excision technique: surgical approach dictated by the location of the HO (anterior or lateral); the HO is excised en bloc where possible; neurovascular structures (sciatic nerve, femoral neurovascular bundle) are at risk in severely ankylosed cases — intraoperative neurophysiological monitoring is recommended for class III–IV HO excision; prophylaxis (NSAIDs or RT) must be commenced immediately post-excision (within 72 hours for RT) to prevent recurrence; without prophylaxis, recurrence after excision approaches 80–90%
Exam Pearls
  • HO after THA: ectopic lamellar bone in periarticular soft tissues; 10–50% radiographic incidence; clinically significant 5–15%; Brooker I–II usually asymptomatic; Brooker III–IV causes pain + restricted motion + potential ankylosis
  • Brooker classification: I (islands of bone — no bridging); II (spurs, gap >1 cm); III (spurs from pelvis AND femur, gap <1 cm); IV (apparent bony ankylosis)
  • Risk factors: prior HO (strongest predictor — ~90% recurrence without prophylaxis); hypertrophic OA; ankylosing spondylitis; DISH; male sex; Paget`s; neurological disease (SCI, TBI)
  • Pathophysiology: BMPs released by surgical trauma → osteoinduction of mesenchymal stem cells → mature lamellar bone; matures over 12–18 months
  • Prophylaxis — indomethacin: 25 mg TDS × 6 weeks; COX inhibition → reduced prostaglandin → reduced osteoblast differentiation; ~50–75% reduction in clinically significant HO; GI + renal side effects; theoretical concern re cementless bone ingrowth (debated)
  • Prophylaxis — radiotherapy: single fraction 7 Gy; within 72 hours of surgery; ablates osteogenic precursors; equivalent efficacy to NSAIDs; preferred in high-risk patients or NSAID contraindication; very low cancer risk at this dose
  • Excision timing: MUST wait for maturity; confirm with bone scan (normalised uptake) + X-ray (cortical margins) + normalised ALP; typically 12–18 months; excision before maturity → 80% recurrence
  • Post-excision prophylaxis mandatory: NSAID or RT within 72 hours after excision; without prophylaxis → 80–90% recurrence; can combine both in highest-risk cases
  • HO vs calcification distinction: HO = mature lamellar bone (organised cortical structure on X-ray); calcification = dystrophic calcium deposition (amorphous, no cortex); clinically and radiographically distinct

References

Brooker AF et al. Ectopic ossification following total hip replacement. J Bone Joint Surg Am. 1973;55(8):1629–1632.
Fransen M et al. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev. 2004.
Vasileiadis GI et al. Heterotopic ossification following total hip arthroplasty — a systematic review. J Arthroplasty. 2012.
Vavken P et al. Efficacy of prophylaxis for heterotopic ossification following hip arthroplasty — a systematic review. J Arthroplasty. 2009.
Pakos EE et al. Radiotherapy for the prevention of heterotopic ossification — a meta-analysis. J Bone Joint Surg Br. 2004.
Campbells Operative Orthopaedics. 14th Edition. Elsevier.
Orthobullets — Heterotopic Ossification after Hip Arthroplasty.
Cipriano CA et al. Heterotopic ossification following hip resurfacing — outcomes and risk factors. J Bone Joint Surg Am. 2009.
NJR Annual Report 2022.
Neal BC et al. Efficacy and safety of radiotherapy for heterotopic ossification — a systematic review. Radiother Oncol. 1997.

Linked Evidence

Indexed papers linked to this topic for quick evidence review.

Search More Evidence

No evidence has been linked to this topic yet.

YOUR ORTHONOTES

Personalize Orthonotes for you

Create a free account and tell us what you're learning. We'll personalize ONE Dashboard around your goals.

Get Started Free →

Already have an account? Log in